Skip to main content

Advertisement

Table 4 Univariate and multivariate analysis of factors associated with sero-protection among children born to HBsAg-positive mothers in four provinces, China 2016–2017

From: Outcomes of the national programme on prevention of mother-to-child transmission of hepatitis B virus in China, 2016–2017

Characteristics No. of observations Anti-HBs Positive Univariate analysis Multivariable analysis
n (%) OR (95% CI) P-value aOR (95% CI) P-value
Maternal age (years)
 18–24 280 272 (97.1) 1.0 (0.4–2.2) 0.8   
 25–34 2992 2893 (96.7) 0.8 (0.5–1.3)    
 35–45 840 816 (97.1)     
Maternal educational level
 Junior middle school or below 1382 1341 (97.0) 1.1 (0.8–1.6) 0.6   
 High Middle school or above 2730 2640 (96.7) 1    
Maternal residence rural / urban
 Rural 2818 2731 (96.9) 1.1 (0.8–1.6) 0.6   
 Urban 1294 1250 (96.6) 1    
Maternal parity
 1 1732 1679 (96.9) 1.1 (0.8–1.5) 0.7   
  > 1 2380 2302 (96.7) 1    
Maternal HBeAg status during this pregnancy
 Positive 1221 1155 (94.6) 0.4 (0.3–0.6) <  0.001# 0.4 (0.3–0.6) <  0.001
 Negative 2740 2681 (97.8) 1   1  
 Unknown 151 145 (96.0) 0.5 (0.2–1.3)   0.6 (0.2–1.3) 0.2
Maternal antiviral treatment during this pregnancy
 Yes 392 377 (96.2) 0.8 (0.5–1.4) 0.5   
 No 3720 3604 (96.9) 1    
Level of delivery hospital
 Prefectural and above 1518 1463 (96.4) 0.8 (0.6–1.1) 0.2   
 County level and below 2594 2518 (97.1) 1    
Mode of delivery
 Vaginal delivery 2349 2271 (96.7) 0.9 (0.6–1.3) 0.6   
 Caesarean section 1763 1710 (97.0) 1    
Child gender
 Male 2185 2118 (96.9) 1.1 (0.8–1.5) 0.6   
 Female 1927 1863 (96.7) 1    
Gestational age (weeks)
  < 37 236 225 (95.3) 0.7 (0.3–1.2) 0.2   
 37–43 3876 3756 (96.9) 1    
Child birth weight (g)
  < 2500 131 122 (93.1) 0.4 (0.2–0.9) 0.02* 0.4 (0.2–0.8) 0.01
 2500–5400 3981 3859 (96.9) 1   1  
Type of HBvacc-BD
 10 μg yeast vaccine 3637 3520 (96.8) 1.3 (0.6–2.7) 0.4   
 20 μg CHO vaccine 285 279 (97.9) 2.0 (0.7–6.0)    
 10 μg CHO vaccine 190 182 (95.8) 1    
Interval between birth and HBvacc-BD (hours)
 Within 12 3579 3467 (96.9) 1 0.5*   
 12–24 466 450 (96.6) 0.9 (0.5–1.5)    
  > 24 67 64 (95.5) 0.7 (0.2-2.2)    
Administered HBIG
 Yes 4092 3961 (96.8) 1.0 (0.96–0.97) 1.0*   
 No 20 20 (100.0) 1    
Interval between 3rd dose HBvacc and HBV serological marker test (months)
  < 7 1666 1635 (98.1) 2.2 (1.5–3.4) <  0.001 2.2 (1.5–3.4) < 0.001
 7–18 2446 2346 (95.9) 1   1  
  1. HBV hepatitis B virus, HBsAg hepatitis B surface antigen, anti-HBs hepatitis B surface antibody, HBvacc hepatitis B vaccine, HBvacc-BD hepatitis B vaccine birth dose, HBIG hepatitis B immunoglobulin, LBW low birth weight, CHO Chinese hamster ovary, #: trend, *: Fisher’s exact test, the factors significant at P < 0.1 in univariate analysis entered into the regression model